D
Dominari Holdings Inc.
DOMH
$6.17
-$0.52-7.77%
D
Sell
2/5/2025Upgraded
Dominari Holdings Inc. (DOMH) was upgraded to D- from E+ on 2/5/2025 due to a substantial increase in the growth index, solvency index and volatility index. Earnings per share increased from -$1.0094 to -$0.6654.
Dominari Holdings Inc. (DOMH) was upgraded to D- from E+ on 2/5/2025 due to a substantial increase in the growth index, solvency index and volatility index. Earnings per share increased from -$1.0094 to -$0.6654.
E
Sell
5/22/2023Downgrade
Dominari Holdings Inc. (DOMH) was downgraded to E+ from D- on 5/22/2023 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 114.34% from -$1.86M to -$3.99M, and EBIT declined 12.4% from -$3.14M to -$3.53M.
Dominari Holdings Inc. (DOMH) was downgraded to E+ from D- on 5/22/2023 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 114.34% from -$1.86M to -$3.99M, and EBIT declined 12.4% from -$3.14M to -$3.53M.
D
Sell
5/17/2023Upgraded
Dominari Holdings Inc. (DOMH) was upgraded to D- from E+ on 5/17/2023 due to an increase in the volatility index and valuation index.
Dominari Holdings Inc. (DOMH) was upgraded to D- from E+ on 5/17/2023 due to an increase in the volatility index and valuation index.
E
Sell
4/27/2023Downgrade
Dominari Holdings Inc. (DOMH) was downgraded to E+ from D- on 4/27/2023 due to a decline in the volatility index.
Dominari Holdings Inc. (DOMH) was downgraded to E+ from D- on 4/27/2023 due to a decline in the volatility index.
D
Sell
4/12/2023Upgraded
Dominari Holdings Inc. (DOMH) was upgraded to D- from E+ on 4/12/2023 due to an increase in the growth index, volatility index and efficiency index. EBIT increased 38.37% from -$5.1M to -$3.14M, and operating cash flow increased 34.96% from -$2.86M to -$1.86M.
Dominari Holdings Inc. (DOMH) was upgraded to D- from E+ on 4/12/2023 due to an increase in the growth index, volatility index and efficiency index. EBIT increased 38.37% from -$5.1M to -$3.14M, and operating cash flow increased 34.96% from -$2.86M to -$1.86M.
E
Sell
11/14/2022Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 11/14/2022 due to a large decline in the growth index and total return index. EBIT declined 121.98% from -$2.3M to -$5.1M, and operating cash flow declined 40.62% from -$2.04M to -$2.86M.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 11/14/2022 due to a large decline in the growth index and total return index. EBIT declined 121.98% from -$2.3M to -$5.1M, and operating cash flow declined 40.62% from -$2.04M to -$2.86M.
D
Sell
11/4/2022Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 11/4/2022 due to a decline in the total return index and volatility index.
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 11/4/2022 due to a decline in the total return index and volatility index.
D
Sell
10/20/2022Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 10/20/2022 due to an increase in the total return index.
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 10/20/2022 due to an increase in the total return index.
D
Sell
10/5/2022Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 10/5/2022 due to a decline in the volatility index.
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 10/5/2022 due to a decline in the volatility index.
D
Sell
9/20/2022Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 9/20/2022 due to an increase in the total return index and volatility index.
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 9/20/2022 due to an increase in the total return index and volatility index.
D
Sell
8/15/2022Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 8/15/2022 due to a large increase in the growth index and valuation index. Operating cash flow increased 46.92% from -$3.84M to -$2.04M, EBIT increased 39.57% from -$3.8M to -$2.3M, and earnings per share increased from -$1.2459 to -$1.1763.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 8/15/2022 due to a large increase in the growth index and valuation index. Operating cash flow increased 46.92% from -$3.84M to -$2.04M, EBIT increased 39.57% from -$3.8M to -$2.3M, and earnings per share increased from -$1.2459 to -$1.1763.
E
Sell
4/18/2022Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 4/18/2022 due to a decline in the total return index and volatility index.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 4/18/2022 due to a decline in the total return index and volatility index.
D
Sell
3/30/2022Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 3/30/2022 due to a substantial decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0005 to -$0.0202, EBIT declined 45.31% from -$1.78M to -$2.59M, and operating cash flow declined 7.96% from -$1.9M to -$2.05M.
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 3/30/2022 due to a substantial decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0005 to -$0.0202, EBIT declined 45.31% from -$1.78M to -$2.59M, and operating cash flow declined 7.96% from -$1.9M to -$2.05M.
D
Sell
11/11/2021Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 11/11/2021 due to an increase in the total return index, growth index and solvency index. Earnings per share increased from -$0.0151 to -$0.0005, and EBIT increased 35.52% from -$2.76M to -$1.78M.
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 11/11/2021 due to an increase in the total return index, growth index and solvency index. Earnings per share increased from -$0.0151 to -$0.0005, and EBIT increased 35.52% from -$2.76M to -$1.78M.
D
Sell
11/8/2021Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index.
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index.
D
Sell
8/13/2021Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 8/13/2021 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$0.0657 to -$0.0151.
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 8/13/2021 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$0.0657 to -$0.0151.
D
Sell
7/7/2021Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 7/7/2021 due to a decline in the volatility index and total return index.
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 7/7/2021 due to a decline in the volatility index and total return index.
D
Sell
6/18/2021Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 6/18/2021 due to an increase in the total return index and volatility index.
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 6/18/2021 due to an increase in the total return index and volatility index.
D
Sell
6/2/2021Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 6/2/2021 due to a decline in the volatility index, efficiency index and valuation index. Net income declined 1,315.34% from $326 to -$3.96M.
AIkido Pharma Inc. (AIKI) was downgraded to D- from D on 6/2/2021 due to a decline in the volatility index, efficiency index and valuation index. Net income declined 1,315.34% from $326 to -$3.96M.
D
Sell
3/23/2021Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 3/23/2021 due to a noticeable increase in the total return index, volatility index and valuation index.
AIkido Pharma Inc. (AIKI) was upgraded to D from D- on 3/23/2021 due to a noticeable increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2021Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 2/8/2021 due to an increase in the total return index and volatility index.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 2/8/2021 due to an increase in the total return index and volatility index.
E
Sell
1/21/2021Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 1/21/2021 due to a decline in the volatility index and valuation index.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 1/21/2021 due to a decline in the volatility index and valuation index.
D
Sell
1/5/2021Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 1/5/2021 due to an increase in the volatility index and total return index.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 1/5/2021 due to an increase in the volatility index and total return index.
E
Sell
12/21/2020Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 12/21/2020 due to a decline in the volatility index.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 12/21/2020 due to a decline in the volatility index.
D
Sell
12/3/2020Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 12/3/2020 due to an increase in the volatility index.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 12/3/2020 due to an increase in the volatility index.
E
Sell
11/16/2020Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 11/16/2020 due to a decline in the efficiency index, growth index and total return index. Operating cash flow declined 26.7% from -$940 to -$1.19M, and total capital declined 7.26% from $31.49M to $29.21M.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 11/16/2020 due to a decline in the efficiency index, growth index and total return index. Operating cash flow declined 26.7% from -$940 to -$1.19M, and total capital declined 7.26% from $31.49M to $29.21M.
D
Sell
8/7/2020Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 8/7/2020 due to an increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.9062 to -$0.0701, net income increased 72.24% from -$8.33M to -$2.31M, and total capital increased 50.15% from $20.98M to $31.49M.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 8/7/2020 due to an increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.9062 to -$0.0701, net income increased 72.24% from -$8.33M to -$2.31M, and total capital increased 50.15% from $20.98M to $31.49M.
E
Sell
8/6/2020Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 8/6/2020 due to a decline in the volatility index.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 8/6/2020 due to a decline in the volatility index.
D
Sell
7/21/2020Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 7/21/2020 due to an increase in the volatility index and growth index.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 7/21/2020 due to an increase in the volatility index and growth index.
E
Sell
5/15/2020Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 5/15/2020 due to a decline in the growth index and efficiency index. Net income declined 956.42% from $973 to -$8.33M, earnings per share declined from $0.2776 to -$0.91, and operating cash flow declined 83.76% from -$788 to -$1.45M.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 5/15/2020 due to a decline in the growth index and efficiency index. Net income declined 956.42% from $973 to -$8.33M, earnings per share declined from $0.2776 to -$0.91, and operating cash flow declined 83.76% from -$788 to -$1.45M.
D
Sell
5/8/2020Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 5/8/2020 due to an increase in the volatility index.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 5/8/2020 due to an increase in the volatility index.
E
Sell
4/21/2020Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 4/21/2020 due to a decline in the solvency index, volatility index and total return index.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 4/21/2020 due to a decline in the solvency index, volatility index and total return index.
D
Sell
4/1/2020Upgraded
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 4/1/2020 due to an increase in the volatility index and valuation index.
AIkido Pharma Inc. (AIKI) was upgraded to D- from E+ on 4/1/2020 due to an increase in the volatility index and valuation index.
E
Sell
3/17/2020Downgrade
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 3/17/2020 due to a decline in the volatility index.
AIkido Pharma Inc. (AIKI) was downgraded to E+ from D- on 3/17/2020 due to a decline in the volatility index.
D
Sell
2/25/2020Upgraded
Spherix Incorporated (SPEX) was upgraded to D- from E+ on 2/25/2020 due to an increase in the volatility index.
Spherix Incorporated (SPEX) was upgraded to D- from E+ on 2/25/2020 due to an increase in the volatility index.
E
Sell
2/4/2020Downgrade
Spherix Incorporated (SPEX) was downgraded to E+ from D- on 2/4/2020 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 252.77% from -$902 to -$3.18M, and operating cash flow declined 28.13% from -$615 to -$788.
Spherix Incorporated (SPEX) was downgraded to E+ from D- on 2/4/2020 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 252.77% from -$902 to -$3.18M, and operating cash flow declined 28.13% from -$615 to -$788.
D
Sell
12/24/2019Downgrade
Spherix Incorporated (SPEX) was downgraded to D- from D on 12/24/2019 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 422.2% from -$644 to -$3.36M, earnings per share declined from -$0.3031 to -$1.377, and total capital declined 23.43% from $11.21M to $8.58M.
Spherix Incorporated (SPEX) was downgraded to D- from D on 12/24/2019 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 422.2% from -$644 to -$3.36M, earnings per share declined from -$0.3031 to -$1.377, and total capital declined 23.43% from $11.21M to $8.58M.
D
Sell
3/13/2019Upgraded
Spherix Incorporated (SPEX) was upgraded to D from D- on 3/13/2019 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 390.96% from -$1.89M to $5.5M, earnings per share increased from -$0.2214 to $0.6405, and total capital increased 83.58% from $6.59M to $12.1M.
Spherix Incorporated (SPEX) was upgraded to D from D- on 3/13/2019 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 390.96% from -$1.89M to $5.5M, earnings per share increased from -$0.2214 to $0.6405, and total capital increased 83.58% from $6.59M to $12.1M.
D
Sell
11/19/2018Downgrade
Spherix Incorporated (SPEX) was downgraded to D- from D on 11/19/2018 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 375.13% from -$398 to -$1.89M, and total capital declined 22.04% from $8.45M to $6.59M.
Spherix Incorporated (SPEX) was downgraded to D- from D on 11/19/2018 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 375.13% from -$398 to -$1.89M, and total capital declined 22.04% from $8.45M to $6.59M.
D
Sell
5/17/2018Upgraded
Spherix Incorporated (SPEX) was upgraded to D from D- on 5/17/2018 due to a significant increase in the efficiency index, solvency index and total return index. The quick ratio increased from 1.63 to 3.96, total capital increased 110.71% from $4.15M to $8.75M, and debt to equity declined from 0.01 to 0.
Spherix Incorporated (SPEX) was upgraded to D from D- on 5/17/2018 due to a significant increase in the efficiency index, solvency index and total return index. The quick ratio increased from 1.63 to 3.96, total capital increased 110.71% from $4.15M to $8.75M, and debt to equity declined from 0.01 to 0.
D
Sell
8/11/2017Downgrade
Spherix Incorporated (SPEX) was downgraded to D- from D on 8/11/2017 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.1859 to -$0.38, net income declined 102.39% from -$919 to -$1.86M, and total capital declined 41.92% from $4.59M to $2.67M.
Spherix Incorporated (SPEX) was downgraded to D- from D on 8/11/2017 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.1859 to -$0.38, net income declined 102.39% from -$919 to -$1.86M, and total capital declined 41.92% from $4.59M to $2.67M.
D
Sell
5/12/2017Upgraded
Spherix Incorporated (SPEX) was upgraded to D from D- on 5/12/2017 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 76.45% from -$3.9M to -$919, earnings per share increased from -$0.8059 to -$0.19, and EBIT increased 17.11% from -$1.17M to -$969.
Spherix Incorporated (SPEX) was upgraded to D from D- on 5/12/2017 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 76.45% from -$3.9M to -$919, earnings per share increased from -$0.8059 to -$0.19, and EBIT increased 17.11% from -$1.17M to -$969.
D
Sell
3/31/2017Upgraded
Spherix Incorporated (SPEX) was upgraded to D- from E+ on 3/31/2017 due to an increase in the efficiency index, volatility index and total return index.
Spherix Incorporated (SPEX) was upgraded to D- from E+ on 3/31/2017 due to an increase in the efficiency index, volatility index and total return index.
E
Sell
11/16/2016Downgrade
Spherix Incorporated (SPEX) was downgraded to E+ from D- on 11/16/2016 due to a decline in the volatility index, efficiency index and total return index.
Spherix Incorporated (SPEX) was downgraded to E+ from D- on 11/16/2016 due to a decline in the volatility index, efficiency index and total return index.
D
Sell
8/17/2016Upgraded
Spherix Incorporated (SPEX) was upgraded to D- from E+ on 8/17/2016 due to a noticeable increase in the valuation index, solvency index and growth index. Operating cash flow increased 319% from -$1.52M to $3.32M, total revenue increased 145.83% from $72 to $177, and the quick ratio increased from 0.83 to 1.64.
Spherix Incorporated (SPEX) was upgraded to D- from E+ on 8/17/2016 due to a noticeable increase in the valuation index, solvency index and growth index. Operating cash flow increased 319% from -$1.52M to $3.32M, total revenue increased 145.83% from $72 to $177, and the quick ratio increased from 0.83 to 1.64.
E
Sell
3/30/2016Downgrade
Spherix Incorporated (SPEX) was downgraded to E+ from D- on 3/30/2016 due to a noticeable decline in the valuation index, efficiency index and solvency index. Net income declined 59.39% from -$2.73M to -$4.35M, and total capital declined 26.6% from $12.48M to $9.16M.
Spherix Incorporated (SPEX) was downgraded to E+ from D- on 3/30/2016 due to a noticeable decline in the valuation index, efficiency index and solvency index. Net income declined 59.39% from -$2.73M to -$4.35M, and total capital declined 26.6% from $12.48M to $9.16M.
D
Sell
3/11/2016Downgrade
Spherix Incorporated (SPEX) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
Spherix Incorporated (SPEX) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
D
Sell
3/3/2016Downgrade
Spherix Incorporated (SPEX) was downgraded to D from D+ on 3/3/2016 due to a decline in the valuation index and volatility index.
Spherix Incorporated (SPEX) was downgraded to D from D+ on 3/3/2016 due to a decline in the valuation index and volatility index.
D
Sell
11/6/2015Upgraded
Spherix Incorporated (SPEX) was upgraded to D+ from D on 11/6/2015 due to a large increase in the growth index and efficiency index.
Spherix Incorporated (SPEX) was upgraded to D+ from D on 11/6/2015 due to a large increase in the growth index and efficiency index.
D
Sell
3/28/2014Upgraded
Spherix Inc. (SPEX) was upgraded to D from on 3/28/2014 due to a significant increase in the solvency index, volatility index and total return index.
Spherix Inc. (SPEX) was upgraded to D from on 3/28/2014 due to a significant increase in the solvency index, volatility index and total return index.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
